SPIL Q2FY27 Financial Results
Read More
At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT® (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
Read More
Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma
Read More
Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care
Read More
Recent Comments